Pseudotumor Cerebri Trial
14728
A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet plus Acetazolamide vs Diet plus Placebo in Subjects with Idiopathic Intracranial Hypertension with Mild Visual Loss
Ophthalmology
Newman Steven, A
Pseudotumor Cerebri IRB-HSR # 14728: Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) The purpose of this study is to determine the efficacy of: (a) the investigational drug Acetazolamide + a weight loss and a dietary counseling program versus (b) Placebo + a weight loss and dietary counseling program in restoring and protecting the vision of patients with mild vision loss secondary to pseudotumor cerebri. Key Eligibility Criteria: 1. Age 18 60 2. Diagnosis of Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri, for 6 weeks or less 3. Any previous treatment for IIH may not have been for more than 1 week 4. Mild visual loss as determined by visual field exam For more information about this study please contact the Clinical Research Coordinator, Kristina Holbrook, at (434) 243-2852 or klh7v@virginia.edu . The principal investigator is Steven A. Newman, M.D.
Ophthalmology Research
Adult
Pseudotumor Cerebri
Eye Disorders
Ophthalmology
Neurology
Ill
No Compensation
Kristina Holbrook
klh7v@virginia.edu
4342432852
